NCT04855929View on ClinicalTrials.gov

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Advanced Solid TumorAdult DiseaseLung Cancer
Interventions
DRUG

ANV419

ANV419 administered by intravenous (IV) infusion

DRUG

Ipilimumab

Ipilimumab administered by intravenous (IV) infusion

Trial Locations (5)

Unknown

Hospital Vall d'Hebrón, Barcelona

START Madrid, Hospital Universitario HM Sanchinarro, Madrid

University Hospital Basel, Basel

Cantonal Hospital St.Gallen, Sankt Gallen

Royal Marsden Hospital, London

Sponsors

Lead Sponsor

Anaveon AG
All Listed Sponsors
lead

Anaveon AG

INDUSTRY

NCT04855929 - A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. | Biotech Hunter | Biotech Hunter